Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
NCT Number: NCT02575885
This randomized pilot clinical trial studies nicotine delivery from novel non-tobacco electronic system (ENDS) in smokers. Studying the levels of nicotine delivered by various types and brands of ENDS to the bloodstream, and comparing this to the levels delivered from conventional cigarettes (the participant's own brand) may help provide information about the use of nicotine-containing products that may help inform/reform current tobacco policy, practice, and harm reduction approaches.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Not applicable
Buffalo, New York, 14263, United States
PRIMARY OBJECTIVES:
I. Determine the levels of nicotine effectively delivered by various types and brands of ENDS to the bloodstream and compare them to levels delivered from conventional cigarettes. (Study 1)
II. Explore the effect of flavorings added to nicotine solution on puffing topography and nicotine delivery and, assess and compare short-term "functional" nicotine effects of the different products by using subjective measures such as relief of craving and withdrawal symptoms. (Study 2)
SECONDARY OBJECTIVES:
I. Determine the amounts of nicotine present in various brands and types of ENDS. (Study 3)
II. Determine nicotine yields in vapors from various types of ENDS under laboratory conditions. (Study 4)
TERTIARY OBJECTIVES:
I. Develop a standardized testing protocol for ENDS that will reflect users' puffing behavior and product characteristics.
II. Develop and validate the analytical method for analysis of nicotine content in the vapor.
III. Propose a standardized puffing regimen for generating vapors for analytical purposes: Such a testing protocol will reflect the puffing behavior observed among ENDS users and should be specific to ENDS type.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I (Study 1): Participants are asked to smoke ad lib a single cigarette of their own brand and provided with a different type of ENDS product at each visit (e-cigarette, disposable e-cigarette, eGo, personal vaporizer, e-cigar, and e-pipe) over 3.5-4 hours at least 7 days apart for 7 weeks. Participants are provided with cartridges of the same amounts of nicotine with regular (tobacco) or menthol flavor according to smoker's preference, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
ARM II (Study 2): Participants are asked to smoke ad lib a single cigarette of their own brand and provided with the BLU e-cigarette ENDS product with nicotine solution of one of five flavors over 3.5-4 hours at least 7 days apart for 6 weeks. Participants are provided with cartridges of maximum available amounts of nicotine and different flavors at each visit, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Receive different type of ENDS product at each visit
Other names: e-Cigarette, Electronic Nicotine Delivery System
Correlative studies
Correlative studies
Ancillary studies
Time frame: Up to 1 year
The maximum concentration of nicotine in plasma (Cmax) will be determined for each product.
Time frame: Up to 1 year
Time to maximum concentration (Tmax) will be determined for each product .
Time frame: up to 1 year
Area under the plasma concentration versus time curve (AUC) will be determined for each product.
Time frame: up to 1 year
Will be measured with Minnesota Withdrawal Scale
Time frame: up to 1 year
Will be measured with Drug Effect Questionnaire
Time frame: up to 1 year
Will be measured with The Positive Negative Affect Scale
Time frame: Up to 1 year
Nicotine content (mean, median, minimum and maximum) will be determined for each product
Time frame: Up to 1 year
Nicotine yield in vapor will be determined for each product.
Time frame: 2 hours post using ENDS product
Cmax will be analyzed using a repeated measures analysis of variance, including terms for gender , race and order of treatment
Time frame: 2 hours post using ENDS product
AUC will be analyzed using a repeated measures analysis of variance, including terms for gender, race and order of treatment.
Time frame: 2 hours post using ENDS product
tmax will be analyzed using a repeated measures analysis of variance, including terms for gender , race and order of treatment
Time frame: 2 hours post using ENDS product
Puff volume as determined with Cress Micro monitors
Time frame: 2 hours post using ENDS product
Puff duration as determined with Cress Micro monitors
Roswell Park Cancer Institute
Other
Nicotine Delivery From Novel Non-tobacco Electronic Systems (ENDS)
Acronym: ENDS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03824535
Behavior, Cigarette Smoker
Palo Alto, California, United States
View Trial DetailsNCT00850954
Cigarette Smoker, Current Smoker
Houston, Texas, United States
View Trial DetailsNCT03199651
Adenocarcinoma, Adenocarcinoma of Lung
Columbus, Ohio, United States
View Trial DetailsNCT03865472
Cigarette Smoker, Current Every Day Smoker
Buffalo, New York, United States
View Trial Details